Skip to main content
NCBI home page
Springer logoLink to Springer
. 2020 Jun 2;80(10):1039–1040. doi: 10.1007/s40265-020-01333-9

Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HoUng Kim 1,2, Rieke Alten 3, Luisa Avedano 4, Axel Dignass 5, Fernando Gomollón 6, Kay Greveson 7, Jonas Halfvarson 8, Peter M Irving 9, Jørgen Jahnsen 10,11, Péter L Lakatos 12,13, JongHyuk Lee 14, Souzi Makri 15, Ben Parker 16,17, Laurent Peyrin-Biroulet 18, Stefan Schreiber 19, Steven Simoens 20, Rene Westhovens 21, Silvio Danese 22,23,✉, Ji Hoon Jeong 2,✉
PMCID: PMC7645575  PMID: 32488813

Correction to: Drugs (2020) 80:99–113 10.1007/s40265-020-01256-5

The affiliation of the corresponding author Silvio Danese, which currently reads,

Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy.

Should read,

IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, via Manzoni 56, 20,089 Rozzano, Milan, Italy.

Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20,090, Pieve Emanuele, Milan, Italy.

Contributor Information

Silvio Danese, Email: sdanese@hotmail.com.

Ji Hoon Jeong, Email: jhjeong3@cau.ac.kr.

Articles from Drugs are provided here courtesy of Springer

RESOURCES